Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 1.44% |
| Q3 2025 | 7.59% |
| Q2 2025 | 21.99% |
| Q1 2025 | -2.85% |
| Q4 2024 | 0.87% |
| Q3 2024 | -10.89% |
| Q2 2024 | 50.74% |
| Q1 2024 | -13.19% |
| Q4 2023 | 16.66% |
| Q3 2023 | 5.38% |
| Q2 2023 | 26.54% |
| Q1 2023 | -10.53% |
| Q4 2022 | 0.38% |
| Q3 2022 | 15.51% |
| Q2 2022 | -5.01% |
| Q1 2022 | 15.54% |
| Q4 2021 | -0.00% |
| Q3 2021 | 10.86% |
| Q2 2021 | 32.73% |
| Q1 2021 | 22.27% |
| Q4 2020 | -15.94% |
| Q3 2020 | 33.50% |
| Q2 2020 | 10.63% |
| Q1 2020 | 25.96% |
| Q4 2019 | -0.05% |
| Q3 2019 | 21.22% |
| Q2 2019 | -7.25% |
| Q1 2019 | 18.36% |
| Q4 2018 | 9.87% |
| Q3 2018 | 32.70% |
| Q2 2018 | 0.42% |
| Q1 2018 | -7.10% |
| Q4 2017 | 56.03% |
| Q3 2017 | -25.65% |
| Q2 2017 | -2.64% |
| Q1 2017 | 20.06% |
| Q4 2016 | -18.37% |
| Q3 2016 | 23.86% |
| Q2 2016 | -5.96% |
| Q1 2016 | -3.08% |